Indivior Pharmaceuticals Inc. Common Stock (INDV)

FairStock Score: 77/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $44 million in annual free cash flow (1.1% yield on market cap)
• Revenue growth of 19.7% demonstrates strong top-line momentum
• FairStock composite score of 77/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

Indivior Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $4.1 billion. The business generates $1.3 billion in annual revenue with a 7.9% net margin and $44 million in free cash flow. From a quality standpoint, Indivior shows Altman Z-Score of 1.9 in the grey zone. On valuation, the stock is reasonably priced at 18.9x earnings, with PEG of 0.26 suggests growth is underpriced. Growth dynamics show revenue growing at 19.7% and profit growth of 72.9%. Our composite FairStock Score of 77/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Indivior's 20% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $44 million in annual free cash flow (1.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer